博安生物:2025中期报告

香港交易所
Sep 29

牛牛AI助手已提取核心信息博安生物2025年上半年收入同比增长8.4%至人民币3.93亿元,产品销售增长15.9%至人民币3.85亿元,实现净利润人民币2,051万元。期内毛利约人民币2.83亿元,毛利率71.8%。销售及经销开支为人民币1.60亿元,研发开支为人民币5,857万元。公司产品组合进一步扩充,第四款产品博优平®(度拉糖肽注射液)于2025年8月获批上市,成为全球首款且唯一获批的度易达...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10